.jpg)
.png)
Spring 2024
Introduction While atherosclerotic cardiovascular disease (ASCVD) and dyslipidemia affect all populations, their impact is far from uniform. Many interwoven factors, including genetics, sociocultural determinants, and environmental exposures, create a diverse picture of risk across different... more
Introduction Immune system activation – i.e., systemic inflammation, plays an essential role in all stages of atherosclerosis, from the development of the fatty streak to acute plaque rupture.1 Autoimmune diseases are common, with a prevalence of up to 8% of the United States (US) adult... more
Dyslipidemia frequently presents in individuals with thyroid dysfunction, attributed to the influence of thyroid hormones on various key metabolic pathways, thereby contributing to an elevated cardiovascular (CV) risk.1 In this discussion, we delve into the intricate connection between thyroid... more
Introduction Chronic kidney disease (CKD) ranks among the top five causes of global mortality, affecting approximately 35.5 million people in the United States (US).1,2 Despite being preventable and treatable, the prevalence of CKD and related mortality are on the rise, making it an important... more
Introduction Normal pregnancy is characterized by physiologic increases in maternal levels of cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). These lipoproteins are taken up by the placenta and support optimal fetal... more
Key points MASLD is a risk factor for atherosclerotic cardiovascular disease and is associated with cardiometabolic risk factors, such as obesity (adiposopathy), hypertension, insulin resistance, diabetes and dyslipidemia. The cornerstone of MASLD management is aggressive treatment of risk... more
Introduction The association of statin use, and incident type 2 diabetes (T2D) is well established in adults.1 Similar observations have not been reported in youth. Despite this association, the benefits of statins in preventing atherosclerotic cardiovascular disease (ASCVD) appear to outweigh... more
There has been robust participation among SWLA members in the National Lipid Association activities and outstanding contributions to the field of lipidology! Here are just a few highlights of what our productive group achieved in 2023! Planned by SWLA leadership, Christie Ballantyne, MD; Nicole... more
It is an honor to contribute this PLA Chapter Update to the current edition of LipidSpin. Congratulations to all PLA and SWLA authors who contributed to this edition. We sincerely appreciate the time and effort involved, and we are also grateful for the mentorship provided by senior authors to... more
Founding Member of the Northeast Lipid Association A physician’s physician A true patient advocate Mentor Friend David Capuzzi, MD, PhD, FNLA, member of the National Lipid Association since 2004, leader in the Northeast Lipid Association, colleague to many, and friend passed away on... more